OneThree Biotech operates a biology-driven artificial intelligence platform focused on optimizing pre-clinical drug discovery and development. The company has validated its approach through Phase 2 trial results with Oncoceutics, which showed treatments identified by its technology could improve average survival from ~3 months to over a year for some patients. OneThree counts partnerships and collaborations with institutions including Weill Cornell Medicine, Cornell Tech, Nvidia, Fox Chase Cancer Center, Cleveland Clinic, The Rockefeller University, Stanford University, and the Icahn School of Medicine at Mount Sinai. The company intends to use the new financing to scale and build out the platform’s backend infrastructure and further validate the technology through partnerships with biotech and pharma. In response to COVID-19, OneThree is offering free AI-based toxicity screening to researchers developing new drugs to treat the disease. The company was founded by Neel S. Madhukar, Ph.D., Olivier Elemento, Ph.D., Coryandar Gilvary, Ph.D., and Bradlay Pryde.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2020